Galapagos BE0003818359

MorphoSys

1. harvester 13 maart 2018 10:36

   auteur info

   • harvester

     Lid sinds: 01 apr 2004

     Laatste bezoek: 09 feb 2025

   • Aanbevelingen

     Ontvangen: 2006

     Gegeven: 1886

   •    Aantal posts: 4.184

   koers reageert positief op de persberichten, nog voor de converence call:
   
   Morphosys AG (MOR.DE)
   XETRA - XETRA Delayed Price. Currency in EUR
   Add to watchlist
   84.75+1.90 (+2.29%)
   
   Alleen maar goed nieuws van Morphosys.
   Sterker geworden in 2017 met een berg cash, en nu ook licentie inkomsten van Tremfya.
   Mogelijk een licentiedeal in 2018 inzake kanker Mor208 en zicht op meer dan EUR 10 miljoen licenties van J+J vanwege Tremfya marktintroductie in US, Canada en als laatste Europa in de 2e helft van 2017,voor de eerst toepassing.
   
   "royalty income (in 2018) from Tremfya(R) ranging from EUR 12 to 17 million at constant exchange rate for the US dollar."
2. harvester 13 maart 2018 23:27

   auteur info

   • harvester

     Lid sinds: 01 apr 2004

     Laatste bezoek: 09 feb 2025

   • Aanbevelingen

     Ontvangen: 2006

     Gegeven: 1886

   •    Aantal posts: 4.184

   quote:

   harvester schreef op 13 maart 2018 10:36:

   koers reageert positief op de persberichten, nog voor de converence call:
   
   Morphosys AG (MOR.DE)
   XETRA - XETRA Delayed Price. Currency in EUR
   Add to watchlist
   84.75+1.90 (+2.29%)
   
   Alleen maar goed nieuws van Morphosys.
   Sterker geworden in 2017 met een berg cash, en nu ook licentie inkomsten van Tremfya.
   Mogelijk een licentiedeal in 2018 inzake kanker Mor208 en zicht op meer dan EUR 10 miljoen licenties van J+J vanwege Tremfya marktintroductie in US, Canada en als laatste Europa in de 2e helft van 2017,voor de eerst toepassing.
   
   "royalty income (in 2018) from Tremfya(R) ranging from EUR 12 to 17 million at constant exchange rate for the US dollar."
   

   Take Home Messages Morphosys conference call:
   
   MOR208
   Focus on developing MOR208 plus lenalidomide in r/r
   DLBCL to approval as fast as possible
   
   MOR202
   Progress, both clinically and in terms of the work we’re doing to secure the program’s future
   
   MOR106
   We focus on working with our partner Galapagos
   on the start of a phase 2 study in Q2 2018
   
   Guselkumab/Tremfya
   Based on Janssen’s announced plans to develop Tremfya
   more broadly in psoriasis as well as in
   psoriatic arthritis and Crohn’s disease, it could become a
   very large and successful drug
   
   link naar presentatie:
   www.morphosys.com/sites/default/files...
   
   Verder kan je ook de jaarrekening downloaden met mooie plaatjes ook over MOR106 en haar werking:
   reports.morphosys.com/2017/
   
   De koers van Morphosys doet het vandaag ook goed en verder gestegen vanaf de 84.75 naar EUR 87.25:
   
   Morphosys AG (MOR.DE)
   XETRA - XETRA
   
   EUR 87.25 +4.40 (+5.31%)
   At close: 5:35PM CET
   Volume 493,661
   Avg. Volume 130,599
   
   Leuk voor de aandeelhouders vanMorphosys waar ik er een van ben.
   Ook fijn voor Galapagos en haar aandeelhouders (waar ik er ook een van ben) dat in Morphosys een sterke partner heeft voor MOR106 en dat dit naar fase 2 gaat in het 2e kwartaal 2018.
   
   Wel gek dat Galapagos dan weer daalt op zo een dag.
3. nelis h 14 maart 2018 08:03

   auteur info

   • nelis h

     Lid sinds: 01 jan 2000

     Laatste bezoek: 10 jan 2025

   • Aanbevelingen

     Ontvangen: 713

     Gegeven: 734

   •    Aantal posts: 3.132

   March 14, 2018 / 7:30 am, CET
   
   Planegg/Munich, Germany, March 14, 2018
   
   
   Clinical Data Presentations at AAT in Alzheimer's Disease Support Investigating Gantenerumab in Higher Doses in New Pivotal Phase 3 Trials
   
   
   
   - Three abstracts will be presented at the upcoming Alzheimer's and Parkinson's Disease conference AAT-AD/PDTM Focus Meeting 2018, thereof one as Late Breaking Abstract.
   
   - Gantenerumab showed greater and consistent amyloid beta reduction in the brain after one year of treatment at higher doses in open label extension (OLE) clinical studies in patients with prodromal to mild Alzheimer's disease compared to lower dosing.
   
   - Results from clinical OLE trials supported higher dosing up to 1200 mg in a slowup-titration regimen compared to doses of 105 mg and 225 mg previously tested in clinical studies.
   
   www.morphosys.com/media-investors/med...
   
4. harvester 19 maart 2018 12:09

   auteur info

   • harvester

     Lid sinds: 01 apr 2004

     Laatste bezoek: 09 feb 2025

   • Aanbevelingen

     Ontvangen: 2006

     Gegeven: 1886

   •    Aantal posts: 4.184

   PLANEGG/MUNICH, GERMANY /ACCESSWIRE / March 14, 2018 / MorphoSys AG (MOR.DE); (MOR.DE); Prime Standard Segment, TecDAX; (OTC PINK: MPSYY) announced today that clinical data supporting the application of gantenerumab in higher doses in new pivotal phase 3 studies for the treatment of Alzheimer's disease planned to start later this year will be presented at AAT-AD/PDTM. In the data presented, gantenerumab was evaluated with considerably higher doses in an open-label extension (OLE) study part than previously tested.
   
   A total of three different abstracts for gantenerumab including one Late Breaking Abstract were accepted for presentation at the upcoming Alzheimer's and Parkinson's Disease conference AAT-AD/PDTM Focus Meeting 2018, which is a new joint meeting between the International Geneva/Springfield Symposium on Advances in Alzheimer Therapy and AD/PDTM, to be held from March 15-18 in Torino, Italy. Gantenerumab is a monoclonal antibody directed against amyloid beta (Aß) developed by Roche for the treatment of Alzheimer's disease that was generated by MorphoSys using its proprietary HuCAL technology.
   
   "The effect of higher doses of gantenerumab on the reduction of amyloid beta in Alzheimer's patients is very encouraging to us", commented Dr. Markus Enzelberger, Chief Scientific Officer of MorphoSys AG.
   
   In the abstract accepted for presentation during the Late Breaking session at the AAT-AD/PDTM, clinical data will be presented assessing clinical effects of higher doses of gantenerumab measured by amyloid beta reduction in the brain. Eighty-one (81) patients with prodromal to mild Alzheimer's disease were enrolled in the OLE study parts and received higher doses of up to 1200 mg gantenerumab subcutaneously every 4 weeks. The dose increase, from starting levels of 105 mg or 225 mg of gantenerumab to up to 1200 mg, was administered using different titration schemes with the goal of controlling potential safety findings due to the increased doses. Fifty-one (51) patients had a brain positron emission tomography (PET) scan to determine amyloid plaques at week 52. According to the data presented, patients who received higher doses of gantenerumab showed a greater and consistent amyloid reduction compared to patients having received lower dosing (105 mg or 225 mg). At week 52, approximately one-third of the high-dose patients had amyloid levels below the threshold that classifies a patient as amyloid beta positive.
   
   Review of the data in the OLE studies did not reveal any new or unexpected safety findings of the higher doses for this patient population. As reported previously (Andjelkovic et al., 2017, CTAD abstract), increased doses of gantenerumab led to an increase of ARIA (amyloid-related imaging abnormalities), which, however, remained manageable with the implemented dosing titration scheme. In the higher doses of up to 1200 mg, severity and seriousness of adverse events was comparable to the lower doses (105 mg or 225 mg) applied in the previous studies.
   
   Details of the presentations about gantenerumab at the AAT-AD/PDTM 2018
   
   Abstract / Oral (Late Breaker) - Analysis of Factors and Methodologic Considerations Affecting Plaque Reduction Measures via PET in the Gantenerumab Open-Label Extension Studies
   Symposium LB1 - Clinical trials in AD, PD, and progressive supranuclear palsy
   Date: Thursday, March 15, 2018
   Time: 10:40 AM - 11:00 AM CET
   Place: Sala 500
   Presenter: Greg Klein
   
   Abstract / Oral presentation- Optimizing the Gantenerumab Phase 3 Dosing Regimen Through PK/PD Modeling and Clinical Trial Simulations
   Symposium 13 - Anti-amyloid Immunotherapies
   Date: Friday, March 16, 2018
   Time: 4:05 PM - 4:25 PM CET
   Place: Sala 500
   Presenter: Carsten Hofmann
5. nelis h 22 maart 2018 20:52

   auteur info

   • nelis h

     Lid sinds: 01 jan 2000

     Laatste bezoek: 10 jan 2025

   • Aanbevelingen

     Ontvangen: 713

     Gegeven: 734

   •    Aantal posts: 3.132

   
   Morphosys gaat naar de Nasdaq !
   
   MorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) Offering
   
   www.morphosys.com/media-investors/med...
   
6. harvester 23 maart 2018 11:29

   auteur info

   • harvester

     Lid sinds: 01 apr 2004

     Laatste bezoek: 09 feb 2025

   • Aanbevelingen

     Ontvangen: 2006

     Gegeven: 1886

   •    Aantal posts: 4.184

   quote:

   nelis h schreef op 22 maart 2018 20:52:

   Morphosys gaat naar de Nasdaq !
   
   MorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) Offering
   
   www.morphosys.com/media-investors/med...
   
   

   Verrassend!
   
   Op zich hebben zij voorlopig niet echt geld nodig.
   Waarom ze het dan wel doen is even de vraag.
   
   Ik kan mijn voorstellen dat institutionals aan de deur hebben geklopt omdat zij op de Duitse markt geen flinke pakketten kunnen kopen.
   Ook Morphosys wordt steeds interessanter voor de grote Pharma's.
   
   Hopelijk horen wij binnenkort meer over de effecten van de patenten strijd met J+J. Daar stond niets over in de jaarrekening, noch in het persbericht.
   Het laatste wat ik erover gehoord was dat het er positief voor hen uitzag en dan mag J+J flink dokken.
   
   Daarnaast loopt Tremfya goed en daar krijgt Morphosys nu royalties over volgend uit de licentieovereenkomst met alweer J+J.
   
   > Also Morphosys future looks bright.
   
   
7. de tuinman 23 maart 2018 16:40

   auteur info

   • de tuinman

     Lid sinds: 15 dec 2009

     Laatste bezoek: 09 feb 2025

   • Aanbevelingen

     Ontvangen: 4030

     Gegeven: 2223

   •    Aantal posts: 12.839

   www.fiercebiotech.com/biotech/morphos...
   
   MorphoSys seeks $150M IPO to fund late-phase anticancer push
8. nelis h 23 maart 2018 18:55

   auteur info

   • nelis h

     Lid sinds: 01 jan 2000

     Laatste bezoek: 10 jan 2025

   • Aanbevelingen

     Ontvangen: 713

     Gegeven: 734

   •    Aantal posts: 3.132

   You need a license to cut-and-paste this copyrighted news content.
   Use this link to purchase your paid subscription ($200/year for individuals and $1,000/year for companies of every size): endpts.com/subscribe
   Already a paid subscriber? Sign in to Endpoints News to remove this message.
   
   MorphoSys, a public company in Germany, is shooting for a dual listing of its shares, hoping to raise $150 million by heading to the Nasdaq. The company is stockpiling cash to take its investigational anti-CD19 antibody, called MOR208, all the way to the market.
   
   MorphoSys already has its shares listed on the German stock exchange, where it draws a $3 billion valuation. It brought in about $83 million in revenue last year, and has a good bit of cash already in the bank. The company says it’s gathering its resources, along with this new IPO in the states, to sink $225 million into the development of MOR208 and an additional $90 million to build out its commercial infrastructure so MorphoSys can handle MOR208’s launch.
   
   The company has plans to seize a quick OK of MOR208, a drug it’s developing for diffuse large B cell lymphoma (DLBCL) and a popular disease target in oncology. After its last batch of upbeat data from a Phase II study of the drug, MorphoSys, which already received breakthrough status for the drug, said it went straight to regulators hoping for early approval.
   
   At this point, the accelerated approval pathway has been blazed by a mob of drugmakers that only needed to show they were doing a reasonable percentage of late-stage patients some good. The FDA has responded with alacrity, and regulators in the US are picking up even more speed under the direction of FDA commissioner Scott Gottlieb. MorphoSys — allied with a group of A-list partners on other drugs — has good reason to believe that they can take the same short cut.
   
   The latest move to list on the Nasdaq gives more fuel to the company’s fire. MorphoSys plans to list under the symbol $MOR.
   
   endpts.com/morphosys-files-for-150m-i...
   
9. harvester 24 maart 2018 09:09

   auteur info

   • harvester

     Lid sinds: 01 apr 2004

     Laatste bezoek: 09 feb 2025

   • Aanbevelingen

     Ontvangen: 2006

     Gegeven: 1886

   •    Aantal posts: 4.184

   quote:

   de tuinman schreef op 23 maart 2018 16:40:

   www.fiercebiotech.com/biotech/morphos...
   
   MorphoSys seeks $150M IPO to fund late-phase anticancer push
   

   En USD 30 miljoen gaan ze stoppen in Mor106.
   Dat gaat dus over de volgende fase van het onderzoek met Galapagos.
   
   Volgens Der Aktionar is het een goede stap van Morphosys.
   
   De volgende partijen verzorgen de plaatsing (volgens het Morphosys bericht op Morphosys.com):
   
   Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Leerink Partners LLC, are acting as lead book-running managers, and Berenberg Capital Markets, LLC and JMP Securities LLC are acting as co-managers for the proposed ADS offering.
   
   Berenberg (uit Dutisland) en Goldman (gisteren) hebben pas hun koersdoel voor Galapagos verhoogd.
   
   Kennelijk zijn beiden overtuigd van de kracht en kansen van Galapagos en van Morphosys.
   De aanloop naar hun commitment naar Morphosys voor deze emissie hebben zij ook wat meer aandacht aan Galapagos besteed.
   
   Nu nog even wachten op wat JPM en zuurpruim Leerink gaan schrijven. Ze moeten in ieder geval positief gaan klinken waar dat hun aandeel in deze emissie ten goede komt.
   
   Op zich verwacht ik een succesvolle plaatsing.
   De cap van USD 150M is waarschijnlijk al gedekt met wat genoemde partijen zelf al aan belangstelling hebben. Het is nu nog even afwachten tegen welke prijs de plaatsing gaat gebeuren. Met de nadruk op het kankeronderzoek verwacht ik een stevige overtekening en en snelle plaatsing.
   
   
10. harvester 27 maart 2018 22:43

    auteur info

    • harvester

      Lid sinds: 01 apr 2004

      Laatste bezoek: 09 feb 2025

    • Aanbevelingen

      Ontvangen: 2006

      Gegeven: 1886

    •    Aantal posts: 4.184

    3/23/2018 Will This Coming IPO Biotech Undercut Gilead, Novartis In Cancer Drugs?
    [Investor's Business Daily]
    
    ALLISON GATLIN
    
    ,Investor's Business Daily•March 23, 2018A German biotech with the potential to rival Gilead Sciences (GILD), Novartis (NVS) and Celgene (CELG) in cancer drugs is looking to raise $150 million in a Nasdaq initial public offering, according to a recent filing.
    
    MorphoSys filed its registration statement in the U.S. on Thursday. It hasn't yet priced the IPO, but in a U.S. Securities and Exchange Commission filing said it plans to raise $150 million. That would help line its coffers as MorphoSys plows ahead with a late-stage oncology drug.
    
    The firm's late-stage treatment would rival approved drugs called CAR-T therapies, which aim to teach a patient's immune system to identify and fight cancer. Novartis and Gilead crossed the finish line last year with CAR-T treatments called Kymriah and Yescarta, respectively.
    
    Kymriah is used to treat a form of acute lymphoblastic leukemia in patients age 25 and younger. Novartis is also seeking approval for Kymriah in a disease called diffuse large B-cell lymphoma, where Gilead's Yescarta is already approved.
11. de tuinman 10 april 2018 12:56

    auteur info

    • de tuinman

      Lid sinds: 15 dec 2009

      Laatste bezoek: 09 feb 2025

    • Aanbevelingen

      Ontvangen: 4030

      Gegeven: 2223

    •    Aantal posts: 12.839

    BRIEF-Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC Filing
    
    www.reuters.com/article/brief-morphos...
12. nelis h 15 april 2018 14:35

    auteur info

    • nelis h

      Lid sinds: 01 jan 2000

      Laatste bezoek: 10 jan 2025

    • Aanbevelingen

      Ontvangen: 713

      Gegeven: 734

    •    Aantal posts: 3.132

    deze week de vaststelling van de IPO uitgiftekoers
    wellicht wat enerverende dagen in het verschiet voor wat vermaak
13. nelis h 18 april 2018 07:23

    auteur info

    • nelis h

      Lid sinds: 01 jan 2000

      Laatste bezoek: 10 jan 2025

    • Aanbevelingen

      Ontvangen: 713

      Gegeven: 734

    •    Aantal posts: 3.132

    vandaag the pricing van de Nasdaq IPO
    de handel zal dan wel spoedig volgen
    
    ----
    
    MorphoSys Resolves a Capital Increase to Implement the Offering of 8,300,000 American Depositary Shares (ADS) in the United States
    MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its Management Board, with the approval of the Supervisory Board, has resolved to increase the share capital of MorphoSys AG by issuing 2,075,000 new ordinary shares from the authorized capital 2017-II, excluding pre-emptive rights of existing shareholders, to implement the initial public offering in the United States of 8,300,000 American Depositary Shares (“ADSs”) pursuant to a Registration Statement on Form F-1, as amended, filed with the U.S. Securities and Exchange Commission. Furthermore, MorphoSys has granted the underwriters a 30-day option to purchase additional ADSs of up to 15% of the total number of ADSs placed in the offering (i.e. 1,245,000 additional ADSs). Each ADS will represent 1/4 of a MorphoSys ordinary share. The new ordinary shares underlying the ADSs represent 8.1% (including the underwriters’ option to purchase additional ADSs) of the registered share capital of MorphoSys prior to the consummation of the capital increase.
    Pricing of the offering is expected to occur on April 18, 2018, following the end of the bookbuilding in the United States.
    Within the United States of America, the securities referred to in this release are offered only by means of a prospectus. A copy of the prospectus can be obtained from Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 1-212-902-9316 or by e-mailing Prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6132, or by e-mailing syndicate@leerink.com.
    A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective
14. HansGarrincha 18 april 2018 13:54

    auteur info

    • HansGarrincha

      Lid sinds: 22 mrt 2004

      Laatste bezoek: 04 aug 2023

    • Aanbevelingen

      Ontvangen: 715

      Gegeven: 138

    •    Aantal posts: 1.398

    Van 2 maart 2018
    www.clinicaltrialsregister.eu/ctr-sea...
    
    Full title of the trial
    A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moderate to severe atopic dermatitis
    A placebo-controlled study to assess efficacy, safety, tolerability and PK/PD of MOR106 in subjects with moderate to severe atopic dermatitis
    
    IGUANA
    
15. nelis h 18 april 2018 21:09

    auteur info

    • nelis h

      Lid sinds: 01 jan 2000

      Laatste bezoek: 10 jan 2025

    • Aanbevelingen

      Ontvangen: 713

      Gegeven: 734

    •    Aantal posts: 3.132

    morgen dus waarschijnlijk al Nasdaq handel
    
    Information regarding the listing of MorphoSys AG (MOR)
    
    Nasdaq anticipates the listing of the initial public offering of MorphoSys AG (MOR) on April 19, 2018. The CUSIP number will be 617760202. The company currently has an existing ADS program that trades on the over the counter market under symbol MPSYY with the CUSIP number 617760103. For reasons of German corporate law, the shares underlying the new ADSs will not be immediately fungible with the shares underlying the existing ADSs. Therefore, the new shares will initially be issued with a separate ISIN, and the new ADS will be issued with a separate CUSIP. This is solely due to the fact that the new shares are not entitled to a (theoretical) dividend for the financial year 2017. Following MorphoSys’ annual general meeting in May, the new shares and the existing shares will become fully fungible and the ADS programs will merge. At that time, the existing ADS program (MPSYY) will merge into the new ADS program and only the Nasdaq listed security (MOR) will exist. Both programs will trade simultaneously until a date to be determined following the annual general meeting on May 17, 2018.
    
    www.phlx.com/TraderNews.aspx?id=ECA20...
    
    
16. nelis h 19 april 2018 07:15

    auteur info

    • nelis h

      Lid sinds: 01 jan 2000

      Laatste bezoek: 10 jan 2025

    • Aanbevelingen

      Ontvangen: 713

      Gegeven: 734

    •    Aantal posts: 3.132

    the pricing :
    
    April 18, 2018 / 11:26 pm, CEST
    
    Planegg/Munich, Germany, April 18, 2018
    
    MorphoSys Announces Pricing of Initial Public Offering of American Depositary Shares (ADSs) on Nasdaq
    
    MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today the pricing of its initial public offering (IPO) in the United States. The offering produced gross proceeds of USD 207,832,000 from the sale of 2,075,000 new ordinary shares in the form of 8,300,000 American Depositary Shares ("ADSs") at a price of USD 25.04 per ADS. Each ADS will represent 1/4 of a MorphoSys ordinary share.
    
    Furthermore, MorphoSys has granted the underwriters an option to purchase up to 1,245,000 additional ADSs, representing 15% of the total number of ADSs placed in the offering. This option can be exercised during the 30-day period commencing April 18, 2018.
    
    The new ordinary shares underlying the ADSs and, if the option will be exercised, the additional ADSs will be issued from MorphoSys's authorized capital 2017-II, excluding pre-emptive rights of existing shareholders and representing up to 8.1% (including the underwriters' option to purchase additional ADSs) of the registered share capital of MorphoSys prior to the consummation of the offering.
    
    MorphoSys's ordinary shares are listed on the Frankfurt Stock Exchange under the symbol "MOR".
    
    The ADSs are expected to begin trading on the Nasdaq Global Market on April 19, 2018, under the symbol "MOR".
    
    - - -
    
    omgerekend ca €80.90 (slot euronext 86.50)
    
17. harvester 19 april 2018 09:00

    auteur info

    • harvester

      Lid sinds: 01 apr 2004

      Laatste bezoek: 09 feb 2025

    • Aanbevelingen

      Ontvangen: 2006

      Gegeven: 1886

    •    Aantal posts: 4.184

    quote:

    nelis h schreef op 19 april 2018 07:15:

    the pricing :
    
    April 18, 2018 / 11:26 pm, CEST
    
    Planegg/Munich, Germany, April 18, 2018
    
    MorphoSys Announces Pricing of Initial Public Offering of American Depositary Shares (ADSs) on Nasdaq
    
    omgerekend ca €80.90 (slot euronext 86.50)
    
    

    Waarom de koers gisteren EUR 86.50 staat begrijp ik dan niet.
    Aangezien het geen flits emissie leek te worden was ik uitgestapt op EUR 82, met het idee later dit jaar weer lager terug te kopen.
    Gezien de emissie prijs zou dat wel kunnen maar gezien de beurskoers van gister nu nog niet. Na de zomer maar weer naar kijken.
    
    Wel heeft Morpho nu meer geld binnen dan voor de huidige plannen nodig.
    Voor MOR 106 volgende fase was USD 30 miljoen gereserveerd volgens het prospectus dus ook Morpho kan haar 50% aandeel in de kosten van dit project met Galapagos makkelijk dragen.
    
    Misschien horen wij meer over MOR106 studie planning bij de 1e kwartaalcijfers van Galapagos.
    
    
    
    
18. nelis h 19 april 2018 10:23

    auteur info

    • nelis h

      Lid sinds: 01 jan 2000

      Laatste bezoek: 10 jan 2025

    • Aanbevelingen

      Ontvangen: 713

      Gegeven: 734

    •    Aantal posts: 3.132

    ik ben niet zo van in en uitstappen
    buy and hold heeft hoog rendenment opgeleverd met Ablynx, ArgenX en Galop (vanaf 2011)
    Vorig jaar positie genomen in MOR (op 56) en die blijft in porto tot MOR208 door fase 3 is. Mag een paar jaar duren.
19. nelis h 26 april 2018 22:18

    auteur info

    • nelis h

      Lid sinds: 01 jan 2000

      Laatste bezoek: 10 jan 2025

    • Aanbevelingen

      Ontvangen: 713

      Gegeven: 734

    •    Aantal posts: 3.132

    (even dit draadje naar boven halen)
    
    Tremfya nu ook goedkeuring voor Zuid Korea
    
20. harvester 1 mei 2018 23:10

    auteur info

    • harvester

      Lid sinds: 01 apr 2004

      Laatste bezoek: 09 feb 2025

    • Aanbevelingen

      Ontvangen: 2006

      Gegeven: 1886

    •    Aantal posts: 4.184

    MorphoSys and Galapagos Announce Initiation of the IGUANA Phase 2 Clinical Trial With MOR106 in Atopic Dermatitis Patients
    You are here
    
    HomeMedia and investorsMedia centerMorphoSys and Galapagos Announce Initiation of...
    
    May 01, 2018 / 10:00 pm, CEST
    
    Planegg/Munich, Germany and Mechelen, Belgium; May 1, 2018
    
    MorphoSys and Galapagos Announce Initiation of the IGUANA Phase 2 Clinical Trial With MOR106 in Atopic Dermatitis Patients
    
    MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR; OTC: MPSYY) and Galapagos NV (Euronext & NASDAQ: GLPG) announced today that the first patient has been enrolled in IGUANA, a phase 2 study with MOR106, an investigational antibody directed against IL-17C, in atopic dermatitis patients.
    
    IGUANA - A MOR106 phase 2 trial
    
    At least 180 patients with moderate-to-severe atopic dermatitis (AD) are planned be treated over a 12-week period with one of three different doses of MOR106 (1, 3 or 10 mg/kg) or placebo using two different dosing regimens in this phase 2 trial in multiple centers across Europe. The placebo controlled, double-blind study will evaluate the efficacy, safety and pharmacokinetics (PK) of MOR106. Dosing at 2 or 4-week intervals will be evaluated over the 12-week treatment period, followed by a 16-week observation period. The primary objective will be assessed by the percentage change from baseline in Eczema Area and Severity Index (EASI) score at week 12.
    
    "Moderate-to-severe AD is a chronic, debilitating disease affecting millions of patients worldwide," said Dr. Malte Peters, Chief Development Officer of MorphoSys AG. "We see a clear unmet medical need for additional safe and efficacious treatment options and we are looking forward to further developing MOR106 for these patients in the phase 2 trial we have now initiated together with our partner Galapagos."
    
    "The IGUANA trial is aimed at providing a robustly supported data set on MOR106 in atopic dermatitis patients. We look forward to seeing what this IL-17C mechanism of action can bring to a larger trial population for longer treatment duration," said Dr. Piet Wigerinck, Chief Scientific Officer of Galapagos.
    
    MOR106 was generated using MorphoSys's Ylanthia antibody platform and is based on a target discovered by Galapagos. IL-17C is a cytokine expressed preferentially in the skin and which has been implicated in dermal inflammation and shown to be distinct from other members of the IL-17 cytokine family. MOR106 is the first publicly known human monoclonal antibody directed against IL-17C in clinical development worldwide. MOR106 is an investigational drug and its safety and efficacy are yet to be established.
    
    About MOR106 results of a phase 1 study in atopic dermatitis (AD)
    Clinical data of a MOR106 Phase 1 trial in AD patients were presented at the American Academy of Dermatology (AAD) conference in February 2018 in San Diego. After 4 infusions in weekly intervals, MOR106 showed preliminary signs of efficacy (5 out of 6 patients responded at the highest dose) and was generally well tolerated (Thaçi et al., 2018, AAD).
    
    About atopic dermatitis
    Atopic dermatitis (AD), the most severe and common type of eczema, is a chronic relapsing inflammatory skin disease that causes severe itch, dry skin and rashes, predominantly on the face, inner side of the elbows and knees, and on hands and feet. Scratching of the affected skin leads to a vicious cycle causing redness, swelling, cracking, scaling of the skin and an increased risk of bacterial infections. Lichenification, thickening of the skin, is characteristic in older children and adults. The National Eczema Association estimates that AD affects over 30 million Americans or up to 25% of children and 2-3% of adults. 60% of AD patients are diagnosed in the first year of life, and 90% of patients have a disease onset before age five. Symptoms commonly fade during childhood, however, approximately 10-30% of the patients will suffer from AD for life. A smaller percentage first develop symptoms as adults.
    
    About IL-17C
    IL-17C is a cytokine that is broadly expressed in human skin pathologies and is described as an important modulator of the innate immune system of the skin, distinct from other members of the IL-17 cytokine family. IL-17C plays a crucial role in human inflammatory conditions, including skin diseases.
    
    About MOR106 and the antibody collaboration of Galapagos and MorphoSys
    MOR106 is an investigational fully human IgG1 monoclonal antibody designed to selectively target IL-17C, currently being developed for treatment of inflammatory diseases. MOR106 arises from the strategic discovery and co-development alliance between Galapagos and MorphoSys, in which both companies contribute their core technologies and expertise. Galapagos has provided the disease-related biology including cellular assays and targets discovered using its target discovery platform. MorphoSys has contributed its Ylanthia antibody technology to generate fully human antibodies directed against the target and contributes full CMC development of this compound. Galapagos and MorphoSys equally share research and development costs, as well as all future economics.